-
公开(公告)号:US20210030752A1
公开(公告)日:2021-02-04
申请号:US17066256
申请日:2020-10-08
申请人: Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc.
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , Jan M.A. van Deursen , Albert Davalos
IPC分类号: A61K31/496 , A61P11/00 , A61P9/10 , A61P27/02 , A61K31/428 , A61K31/495 , A61K31/5377 , C12N15/113 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US20200030323A1
公开(公告)日:2020-01-30
申请号:US16584638
申请日:2019-09-26
申请人: Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc.
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Jan M.A. van Deursen
IPC分类号: A61K31/496 , A61P11/00 , A61P9/10 , A61P27/02 , A61K31/428 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US10478433B2
公开(公告)日:2019-11-19
申请号:US16007880
申请日:2018-06-13
申请人: Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jan M. A. van Deursen , Alain Philippe Vasserot , Bennett G. Childs
IPC分类号: A61K31/496 , A61P27/02 , A61P27/06 , A61K9/00 , A61P11/00 , A61P9/10 , A61K31/428 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , C12Q1/48
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US20180139939A1
公开(公告)日:2018-05-24
申请号:US15870172
申请日:2018-01-12
IPC分类号: A01K67/027 , A61K49/00 , C12N15/85
CPC分类号: A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0393 , A61K49/0008 , C12N15/8509 , C12N2015/859 , C12N2830/008
摘要: This disclosure provides non-human animal models for age-related disorders and age-sensitive traits, particularly those caused by senescence-inducing stimuli, wherein the models comprise transgenes selectively expressed by senescent cells. The disclosure further provides methods for identifying therapeutic agents effective for treating or preventing age-related disorders and age-sensitive traits using the animal models, therapeutic agents identified using such methods, pharmaceutical compositions comprising the identified therapeutic agents, and methods of treating or preventing age-related disorders and age-sensitive traits.
-
公开(公告)号:US20180000816A1
公开(公告)日:2018-01-04
申请号:US15675171
申请日:2017-08-11
IPC分类号: A61K31/496 , A61K9/00
CPC分类号: A61K31/635 , A61K8/00 , A61K9/0019 , A61K9/0048 , A61K9/0073 , A61K9/12 , A61K31/496 , A61K31/675
摘要: A library of heterocyclic compounds has been screened to identify particular compounds that have high inhibitory capacity for the Bcl family of regulatory proteins. Compounds identified as Bcl antagonists have been further screened to select pharmaceutical agents with both high potency and high specificity for eliminating senescent cells in comparison with replicative or quiescent cells of the same tissue type. Particular structures are identified in this disclosure that eliminate senescent cells with an EC50 in the nanomole range and a specificity around or above 100-fold. In accordance with this invention, heterocyclic compounds provided in this disclosure can be formulated for the treatment of a range of age-related conditions caused or mediated by senescent cells. Such conditions are exemplified by ophthalmic conditions, pulmonary conditions, and osteoarthritis.
-
6.
公开(公告)号:US09849128B2
公开(公告)日:2017-12-26
申请号:US15455575
申请日:2017-03-10
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research , The John Hopkins University
发明人: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jennifer Elisseeff , Chaekyu Kim , Okhee Jeon
IPC分类号: A61K31/417 , A61K31/496 , A61K31/728 , A61K31/4178
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , C12N5/0081 , C12N2501/999 , C12N2503/02
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
7.
公开(公告)号:US20170198253A1
公开(公告)日:2017-07-13
申请号:US15455684
申请日:2017-03-10
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research , The John Hopkins University
发明人: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , Darren J. Baker , Bennett G. Childs , James L. Kirkland , Tamar Tchkonia , Jan M.A. van Deursen , Jennifer Elisseeff , Chaekyu Kim , Okhee Jeon , Allyson K. Palmer
IPC分类号: C12N5/00
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , A61P11/00 , C12N5/0081 , C12N2501/999 , C12N2503/02
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
8.
公开(公告)号:US20170196858A1
公开(公告)日:2017-07-13
申请号:US15455630
申请日:2017-03-10
申请人: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research , The John Hopkins University
发明人: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , Darren J. Baker , Bennett G. Childs , James L. Kirkland , Tamar Tchkonia , Jan M.A. van Deursen , Jennifer Elisseeff , Chaekyu Kim , Okhee Jeon , Allyson K. Palmer
IPC分类号: A61K31/496 , C12N5/00
CPC分类号: A61K31/496 , A61K9/0048 , A61K9/0073 , A61K31/404 , A61K31/4178 , A61K31/428 , A61K31/4375 , A61K31/495 , A61K31/5377 , A61K31/728 , A61K45/06 , A61K47/36 , A61P9/10 , A61P11/00 , A61P27/02 , C12N5/0081 , C12N2501/999 , C12N2503/02 , C12Q1/485
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号:US20200338094A1
公开(公告)日:2020-10-29
申请号:US16893012
申请日:2020-06-04
IPC分类号: A61K31/635 , A61K31/496 , A61K31/675 , A61K9/00 , A61K9/12 , A61K8/00
摘要: A library of heterocyclic compounds has been screened to identify particular compounds that have high inhibitory capacity for the Bcl family of regulatory proteins. Compounds identified as Bcl antagonists have been further screened to select pharmaceutical agents with both high potency and high specificity for eliminating senescent cells in comparison with replicative or quiescent cells of the same tissue type. Particular structures are identified in this disclosure that eliminate senescent cells with an EC50 in the nanomole range and a specificity around or above 100-fold. In accordance with this invention, heterocyclic compounds provided in this disclosure can be formulated for the treatment of a range of age-related conditions caused or mediated by senescent cells. Such conditions are exemplified by ophthalmic conditions, pulmonary conditions, and osteoarthritis.
-
公开(公告)号:US10328073B2
公开(公告)日:2019-06-25
申请号:US16054667
申请日:2018-08-03
申请人: Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Bennett G. Childs , Jan M. A. van Deursen
IPC分类号: A61K31/496 , A61P27/02 , A61P11/00 , A61P9/10 , A61K31/428 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00
摘要: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
-
-
-
-
-
-
-
-